

TRYING 31.6 11792...100%

```
***** BEGINUNLIMITED TALKING INTERNATIONAL *****
FILE "EMERSON" ENTERED AT 16:01:18 ON 19 AUG 2011
TELEPHIGHT C 1000 EMERSON 5
FILE "EMERSON" ENTERED AT 16:01:18 ON 19 AUG 2011
TELEPHIGHT C 1000 AMERICAN MEMOIR CIVILTY AND
FILE "EMERSON" ENTERED AT 16:01:18 ON 19 AUG 2011
TELEPHIGHT C 1000 Emerson Science B.V. All rights reserved.
FILE "BISSEK" ENTERED AT 16:01:18 ON 19 AUG 2011
TELEPHIGHT C 1000 BISSEK 5
JEN INTERNATIONAL LOGOFF AT 16:01:48 ON 19 AUG 2011
```

File 111 via Winslow to STN

Trying 31.691692...Open

TABLE 1

DESCRIPTIVE STATISTICS

\* \* \* \* \* Welcome to CNN International \* \* \* \* \*

NEWS 1 WAX Page URLs for STN Seminar Schedule - N. America  
NEWS 2 The Oxford link available in the CASUS and A files  
NEWS 3 Shy: Sharing information Synchpass files have new names  
NEWS 4 CASUS now online being updated  
NEWS 5 Search for compounds by chemical structure  
NEWS 6 PRE-1989 REFERENCES NOW SEARCHABLE IN CASUS AND CA  
NEWS 7 LUNNE Reload  
NEWS 8 Published patent applications AI are now in WHATFILL  
NEWS 9 NEW SII alert frequency now available in Internet  
LWIR and IIR

NEWS EXPRESS    Awaiting the "PREFACE WIND WEATHER" is called.  
                   "PERMIT TRAINING" is being done. EN, AM, and  
 NEWS HOURS    AM, "PREFACE" is being done. EN, AM, and  
 NEWS INTER    AM, "PREFACE" is being done. EN, AM, and  
 NEWS LOGIN    AM, "PREFACE" is being done. EN, AM, and  
 NEWS PHONE    AM, "PREFACE" is being done. EN, AM, and  
 NEWS WWW      AM, "PREFACE" is being done. EN, AM, and

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer Agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

..... *Prunella* ..... *Prunella* .....

**KEY WORDS:** ENTERIC; AROMATASE INHIBITORS

[illegible]

UNIT IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SECTION
FILE ESTIMATE: 191	191	191

FILE 'MELLINE' ENTERED AT 161242Z ON 10 AUG 82

$$\begin{aligned} \frac{\partial}{\partial t} \left( \frac{1}{2} \rho \mathbf{u} \cdot \mathbf{u} \right) + \nabla \cdot \left( \frac{1}{2} \rho \mathbf{u} \otimes \mathbf{u} \right) &= \frac{\partial}{\partial t} \left( \frac{1}{2} \rho \mathbf{u} \cdot \mathbf{u} \right) + \nabla \cdot \left( \frac{1}{2} \rho \mathbf{u} \otimes \mathbf{u} \right) \\ &= \frac{\partial}{\partial t} \left( \frac{1}{2} \rho \mathbf{u} \cdot \mathbf{u} \right) + \nabla \cdot \left( \frac{1}{2} \rho \mathbf{u} \otimes \mathbf{u} \right) \end{aligned}$$

THE UNIVERSITY OF CHICAGO PRESS

1. *Journal of the American Medical Association*, 1997; 277: 1033-1038.

THE UNIVERSITY OF CHICAGO PRESS

THE UNIVERSITY OF CHICAGO PRESS

[illegible]

1. The first step is to identify the key components of the system. This includes understanding the hardware, software, and data involved.

0 8 ANTIH49 IFN INTERFERON GAMMA 15 IFN GAMMA 15 GAMMA INTERFERON 15 HEP-IFN  
M 1469 ANTIGEN: IHN INTERFERON GAMMA 15 IFN GAMMA 15 GAMMA  
INTERFERON OR GAMMA IFN

2. 2 antibody: TNF or TNF alpha or tumor necrosis factor alpha or TNF beta or tumor necrosis factor beta

1. The first group of respondents (Group 1) consisted of 100 individuals who were randomly selected from the population of 1,000. This group was used to estimate the overall population mean and standard deviation.

1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100. 101. 102. 103. 104. 105. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115. 116. 117. 118. 119. 120. 121. 122. 123. 124. 125. 126. 127. 128. 129. 130. 131. 132. 133. 134. 135. 136. 137. 138. 139. 140. 141. 142. 143. 144. 145. 146. 147. 148. 149. 150. 151. 152. 153. 154. 155. 156. 157. 158. 159. 160. 161. 162. 163. 164. 165. 166. 167. 168. 169. 170. 171. 172. 173. 174. 175. 176. 177. 178. 179. 180. 181. 182. 183. 184. 185. 186. 187. 188. 189. 190. 191. 192. 193. 194. 195. 196. 197. 198. 199. 200. 201. 202. 203. 204. 205. 206. 207. 208. 209. 210. 211. 212. 213. 214. 215. 216. 217. 218. 219. 220. 221. 222. 223. 224. 225. 226. 227. 228. 229. 230. 231. 232. 233. 234. 235. 236. 237. 238. 239. 240. 241. 242. 243. 244. 245. 246. 247. 248. 249. 250. 251. 252. 253. 254. 255. 256. 257. 258. 259. 260. 261. 262. 263. 264. 265. 266. 267. 268. 269. 270. 271. 272. 273. 274. 275. 276. 277. 278. 279. 280. 281. 282. 283. 284. 285. 286. 287. 288. 289. 290. 291. 292. 293. 294. 295. 296. 297. 298. 299. 300. 301. 302. 303. 304. 305. 306. 307. 308. 309. 310. 311. 312. 313. 314. 315. 316. 317. 318. 319. 320. 321. 322. 323. 324. 325. 326. 327. 328. 329. 330. 331. 332. 333. 334. 335. 336. 337. 338. 339. 340. 341. 342. 343. 344. 345. 346. 347. 348. 349. 350. 351. 352. 353. 354. 355. 356. 357. 358. 359. 360. 361. 362. 363. 364. 365. 366. 367. 368. 369. 370. 371. 372. 373. 374. 375. 376. 377. 378. 379. 380. 381. 382. 383. 384. 385. 386. 387. 388. 389. 390. 391. 392. 393. 394. 395. 396. 397. 398. 399. 400. 401. 402. 403. 404. 405. 406. 407. 408. 409. 410. 411. 412. 413. 414. 415. 416. 417. 418. 419. 420. 421. 422. 423. 424. 425. 426. 427. 428. 429. 430. 431. 432. 433. 434. 435. 436. 437. 438. 439. 440. 441. 442. 443. 444. 445. 446. 447. 448. 449. 450. 451. 452. 453. 454. 455. 456. 457. 458. 459. 460. 461. 462. 463. 464. 465. 466. 467. 468. 469. 470. 471. 472. 473. 474. 475. 476. 477. 478. 479. 480. 481. 482. 483. 484. 485. 486. 487. 488. 489. 490. 491. 492. 493. 494. 495. 496. 497. 498. 499. 500. 501. 502. 503. 504. 505. 506. 507. 508. 509. 510. 511. 512. 513. 514. 515. 516. 517. 518. 519. 520. 521. 522. 523. 524. 525. 526. 527. 528. 529. 530. 531. 532. 533. 534. 535. 536. 537. 538. 539. 540. 541. 542. 543. 544. 545. 546. 547. 548. 549. 550. 551. 552. 553. 554. 555. 556. 557. 558. 559. 560. 561. 562. 563. 564. 565. 566. 567. 568. 569. 570. 571. 572. 573. 574. 575. 576. 577. 578. 579. 580. 581. 582. 583. 584. 585. 586. 587. 588. 589. 590. 591. 592. 593. 594. 595. 596. 597. 598. 599. 600. 601. 602. 603. 604. 605. 606. 607. 608. 609. 610. 611. 612. 613. 614. 615. 616. 617. 618. 619. 620. 621. 622. 623. 624. 625. 626. 627. 628. 629. 630. 631. 632. 633. 634. 635. 636. 637. 638. 639. 640. 641. 642. 643. 644. 645. 646. 647. 648. 649. 650. 651. 652. 653. 654. 655. 656. 657. 658. 659. 660. 661. 662. 663. 664. 665. 666. 667. 668. 669. 670. 671. 672. 673. 674. 675. 676. 677. 678. 679. 680. 681. 682. 683. 684. 685. 686. 687. 688. 689. 690. 691. 692. 693. 694. 695. 696. 697. 698. 699. 700. 701. 702. 703. 704. 705. 706. 707. 708. 709. 710. 711. 712. 713. 714. 715. 716. 717. 718. 719. 720. 721. 722. 723. 724. 725. 726. 727. 728. 729. 730. 731. 732. 733. 734. 735. 736. 737. 738. 739. 740. 741. 742. 743. 744. 745. 746. 747. 748. 749. 750. 751. 752. 753. 754. 755. 756. 757. 758. 759. 760. 761. 762. 763. 764. 765. 766. 767. 768. 769. 770. 771. 772. 773. 774. 775. 776. 777. 778. 779. 780. 781. 782. 783. 784. 785. 786. 787. 788. 789. 790. 791. 792. 793. 794. 795. 796. 797. 798. 799. 800. 801. 802. 803. 804. 805. 806. 807. 808. 809. 810. 811. 812. 813. 814. 815. 816. 817. 818. 819. 820. 821. 822. 823. 824. 825. 826. 827. 828. 829. 830. 831. 832. 833. 834. 835. 836. 837. 838. 839. 840. 84

Figure 1. The effect of the concentration of the *Agrobacterium* suspension on the transformation efficiency of *Agrobacterium* strains. The *Agrobacterium* strains were grown in YEA medium for 24 h at 28 °C. The cell concentration was adjusted to 10<sup>8</sup> cells/ml. The cell suspension was mixed with the plant tissue and incubated for 24 h at 28 °C. The plant tissue was then cultured on the selective medium. The transformation efficiency was determined as the number of transformants per 100 mg of plant tissue. The data are the mean ± SD of three independent experiments.

1. *Journal of the American Medical Association*, 1997; 277: 1033-1037.

the 1990s, the number of people in the world who are illiterate has increased from 750 million to 850 million. The number of illiterate people in the world is still increasing, and the rate of illiteracy is still high. In 1990, the rate of illiteracy was 21.5% in the world, 27.5% in the developing countries, and 35.5% in the least developed countries. In 2000, the rate of illiteracy was 21.5% in the world, 27.5% in the developing countries, and 35.5% in the least developed countries. In 2010, the rate of illiteracy was 21.5% in the world, 27.5% in the developing countries, and 35.5% in the least developed countries. In 2015, the rate of illiteracy was 21.5% in the world, 27.5% in the developing countries, and 35.5% in the least developed countries. In 2020, the rate of illiteracy was 21.5% in the world, 27.5% in the developing countries, and 35.5% in the least developed countries. In 2025, the rate of illiteracy was 21.5% in the world, 27.5% in the developing countries, and 35.5% in the least developed countries. In 2030, the rate of illiteracy was 21.5% in the world, 27.5% in the developing countries, and 35.5% in the least developed countries. In 2035, the rate of illiteracy was 21.5% in the world, 27.5% in the developing countries, and 35.5% in the least developed countries. In 2040, the rate of illiteracy was 21.5% in the world, 27.5% in the developing countries, and 35.5% in the least developed countries. In 2045, the rate of illiteracy was 21.5% in the world, 27.5% in the developing countries, and 35.5% in the least developed countries. In 2050, the rate of illiteracy was 21.5% in the world, 27.5% in the developing countries, and 35.5% in the least developed countries. In 2055, the rate of illiteracy was 21.5% in the world, 27.5% in the developing countries, and 35.5% in the least developed countries. In 2060, the rate of illiteracy was 21.5% in the world, 27.5% in the developing countries, and 35.5% in the least developed countries. In 2065, the rate of illiteracy was 21.5% in the world, 27.5% in the developing countries, and 35.5% in the least developed countries. In 2070, the rate of illiteracy was 21.5% in the world, 27.5% in the developing countries, and 35.5% in the least developed countries. In 2075, the rate of illiteracy was 21.5% in the world, 27.5% in the developing countries, and 35.5% in the least developed countries. In 2080, the rate of illiteracy was 21.5% in the world, 27.5% in the developing countries, and 35.5% in the least developed countries. In 2085, the rate of illiteracy was 21.5% in the world, 27.5% in the developing countries, and 35.5% in the least developed countries. In 2090, the rate of illiteracy was 21.5% in the world, 27.5% in the developing countries, and 35.5% in the least developed countries. In 2095, the rate of illiteracy was 21.5% in the world, 27.5% in the developing countries, and 35.5% in the least developed countries. In 2100, the rate of illiteracy was 21.5% in the world, 27.5% in the developing countries, and 35.5% in the least developed countries.

1000

145 1973

THE CHAIRMAN: I am pleased to have you here, and I am pleased to have you here.

03 DEC 88 113 EVELYNES REMOVED

100-100000

THE UNIVERSITY OF CHICAGO PRESS

[illegible]

1. *Chlorophyll a* and *Chlorophyll b* were determined by the method of Lichtenthaler and Sponholz (1980).

[illegible]

Table 1. *Salmonella* serotypes and their associated diseases

Table 1. *Continued*

$$= \frac{1}{2} \left( \frac{1}{2} + \frac{1}{2} \right) = \frac{1}{2}$$
[illegible]

**AUTHOR'S ADDRESS:** Dr. G. J. van Erp, Department of Psychology, University of Amsterdam, PO Box 9106, NL-1007 CB Amsterdam, The Netherlands; e-mail: g.j.vanerp@psych.uva.nl

[illegible]

TABLE 1  
 The first two moments of the distribution of the number of successes with the  
 first two trials of the  $IPN=1000$  and the first two trials of the  $IPN=1000$  and  
 the first two trials of the  $IPN=1000$  and the first two trials of the  $IPN=1000$

|      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |        |
|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|--------|
| 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 | 2036 | 2037 | 2038 | 2039 | 2040 | 2041 | 2042 | 2043 | 2044 | 2045 | 2046 | 2047 | 2048 | 2049 | 2050 | 2051 | 2052 | 2053 | 2054 | 2055 | 2056 | 2057 | 2058 | 2059 | 2060 | 2061 | 2062 | 2063 | 2064 | 2065 | 2066 | 2067 | 2068 | 2069 | 2070 | 2071 | 2072 | 2073 | 2074 | 2075 | 2076 | 2077 | 2078 | 2079 | 2080 | 2081 | 2082 | 2083 | 2084 | 2085 | 2086 | 2087 | 2088 | 2089 | 2090 | 2091 | 2092 | 2093 | 2094 | 2095 | 2096 | 2097 | 2098 | 2099 | 2100 | 2101 | 2102 | 2103 | 2104 | 2105 | 2106 | 2107 | 2108 | 2109 | 2110 | 2111 | 2112 | 2113 | 2114 | 2115 | 2116 | 2117 | 2118 | 2119 | 2120 | 2121 | 2122 | 2123 | 2124 | 2125 | 2126 | 2127 | 2128 | 2129 | 2130 | 2131 | 2132 | 2133 | 2134 | 2135 | 2136 | 2137 | 2138 | 2139 | 2140 | 2141 | 2142 | 2143 | 2144 | 2145 | 2146 | 2147 | 2148 | 2149 | 2150 | 2151 | 2152 | 2153 | 2154 | 2155 | 2156 | 2157 | 2158 | 2159 | 2160 | 2161 | 2162 | 2163 | 2164 | 2165 | 2166 | 2167 | 2168 | 2169 | 2170 | 2171 | 2172 | 2173 | 2174 | 2175 | 2176 | 2177 | 2178 | 2179 | 2180 | 2181 | 2182 | 2183 | 2184 | 2185 | 2186 | 2187 | 2188 | 2189 | 2190 | 2191 | 2192 | 2193 | 2194 | 2195 | 2196 | 2197 | 2198 | 2199 | 2200 | 2201 | 2202 | 2203 | 2204 | 2205 | 2206 | 2207 | 2208 | 2209 | 2210 | 2211 | 2212 | 2213 | 2214 | 2215 | 2216 | 2217 | 2218 | 2219 | 2220 | 2221 | 2222 | 2223 | 2224 | 2225 | 2226 | 2227 | 2228 | 2229 | 2230 | 2231 | 2232 | 2233 | 2234 | 2235 | 2236 | 2237 | 2238 | 2239 | 2240 | 2241 | 2242 | 2243 | 2244 | 2245 | 2246 | 2247 | 2248 | 2249 | 2250 | 2251 | 2252 | 2253 | 2254 | 2255 | 2256 | 2257 | 2258 | 2259 | 2260 | 2261 | 2262 | 2263 | 2264 | 2265 | 2266 | 2267 | 2268 | 2269 | 2270 | 2271 | 2272 | 2273 | 2274 | 2275 | 2276 | 2277 | 2278 | 2279 | 2280 | 2281 | 2282 | 2283 | 2284 | 2285 | 2286 | 2287 | 2288 | 2289 | 2290 | 2291 | 2292 | 2293 | 2294 | 2295 | 2296 | 2297 | 2298 | 2299 | 2300 | 2301 | 2302 | 2303 | 2304 | 2305 | 2306 | 2307 | 2308 | 2309 | 2310 | 2311 | 2312 | 2313 | 2314 | 2315 | 2316 | 2317 | 2318 | 2319 | 2320 | 2321 | 2322 | 2323 | 2324 | 2325 | 2326 | 2327 | 2328 | 2329 | 2330 | 2331 | 2332 | 2333 | 2334 | 2335 | 2336 | 2337 | 2338 | 2339 | 2340 | 2341 | 2342 | 2343 | 2344 | 2345 | 2346 | 2347 | 2348 | 2349 | 2350 | 2351 | 2352 | 2353 | 2354 | 2355 | 2356 | 2357 | 2358 | 2359 | 2360 | 2361 | 2362 | 2363 | 2364 | 2365 | 2366 | 2367 | 2368 | 2369 | 2370 | 2371 | 2372 | 2373 | 2374 | 2375 | 2376 | 2377 | 2378 | 2379 | 2380 | 2381 | 2382 | 2383 | 2384 | 2385 | 2386 | 2387 | 2388 | 2389 | 2390 | 2391 | 2392 | 2393 | 2394 | 2395 | 2396 | 2397 | 2398 | 2399 | 2400 | 2401 | 2402 | 2403 | 2404 | 2405 | 2406 | 2407 | 2408</ |
|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|--------|

Address: 10000 Wilshire Blvd., Suite 1000, Beverly Hills, CA 90210  
 Phone: (310) 277-1000  
 Fax: (310) 277-1001  
 E-mail: [info@bentley.com](mailto:info@bentley.com)  
 Web: <http://www.bentley.com>

[illegible]

3. REFERENCE: JOURNAL OF POLITICAL ECONOMY, 1957 May, Vol. 65, No. 3, pp. 1-11.

$$Z = \{Z_1, Z_2, \dots, Z_n\} \text{ is a } (n, k, \lambda) \text{ design, where } n = \text{number of points, } k = \text{number of points in each block, and } \lambda = \text{number of blocks containing any two points.}$$

FOR THE UNITED STATES

LANGUAGE: English

FILE COMMENT: Abridged Index Medicus Journals; Priority Journals

ENTRY MONTH: 1968

ENTRY DATE: Entered STN: 19900308

Last Updated on STN: 1997.03

Entered Medline 19880603

AB5 Organisms belonging to the Mycobacterium avium complex (MAC) are the most common bacterial pathogens in patients with AIDS but factors associated with the activation of cellular defense mechanisms against this atypical mycobacterium have not been defined. Peritoneal macrophages harvested from a murine MAC infection in C57 black mice are able to kill approximately 60% of intracellular MAC in contrast to 20% killing by untreated human and mouse macrophages in vitro. The availability of murine rTNF- $\alpha$ , rTNF- $\beta$ , and rTNF- $\gamma$  permitted evaluation of the role of each of these lymphokines in macrophage activation. Infection, in activating macrophages in vitro to kill MAC, human macrophage-derived macrophages were cultured in vitro, stimulated with rIL-2, rIFN- $\gamma$ , or rTNF, and then infected with MAC (serovars 1 and 4). Mouse peritoneal macrophages were harvested, cultured in vitro, and stimulated with rIL-2, rIFN- $\gamma$ , or rTNF. rIL-2 was associated with a modest increase of intracellular killing of MAC (2+ to 3+), even when utilized 24 or 48 h after macrophage infection or when administered for 5 consecutive days after infection. rIL-2 + 4. Both human and murine IFN- $\gamma$  were associated with increased intracellular growth of MAC (3+ to 4+ for murine and 2+ to 3+ for human macrophages). However, intracellular killing of MAC acquired with rIL-2 was increased after 48 h of treatment with IFN- $\gamma$ . This latter effect was fully blocked by anti-TNF antibody, whereas rIL-2 alone did not augment the intracellular killing of MAC in human macrophages. rTNF- $\alpha$  with rIFN- $\gamma$  or rIL-2 triggered significant increases in superoxide anion production, but subsequent MAC killing was greater than with rTNF alone. Treatment of macrophages with 10 U/ml of rTNF followed by rIL-2 (10 U/ml) was associated with 60% of intracellular killing. TNF seems to be an important molecule, promoting activation of mycobactericidal mechanisms in human macrophages.

A5 Organisms belonging to the *Mycobacterium avium* complex (MAC) are the most common bacterial pathogens in patients with AIDS but factors associated with the ability for cellular defense mechanisms against this atypical mycobacterium have not been defined. Peritoneal macrophages, 1 of intracellular killing of MAC 54-10-1 even when utilized 24 hr after macrophage infection or when administered for 5 consecutive days after infection (1,2,3,4). Both human and murine IFN-gamma were associated with increased intracellular growth of MAC for human macrophages (5). However, intracellular killing of MAC is impaired with control was observed after 4 days of treatment with IFN-gamma. This latter effect was fully corrected by treatment with IFN-gamma antibody, whereas IFN-gamma did not augment the intracellular killing of MAC by human macrophages. IFN-gamma either IFN-gamma or IFN-gamma antibody.

As a result, the model is able to capture the nonlinear relationship between the variables and the response variable, and the model is able to capture the nonlinear relationship between the variables and the response variable.

### ACKNOWLEDGMENTS

**CONSENT NOTICE:** I have read and understand the above information and agree to the terms and conditions of the above program. I understand that my participation in this program is voluntary and that I may withdraw at any time without penalty. I understand that my participation in this program may be terminated at any time without notice. I understand that my participation in this program may be terminated at any time without notice. I understand that my participation in this program may be terminated at any time without notice.

**Abstract:** Antiretroviral therapy and CD4 counts are important determinants of the development of opportunistic infections. The purpose of this study was to determine the prevalence of opportunistic infections in patients with HIV/AIDS.

With a 3 : 1

Figure 1. The effect of the concentration of the *Agrobacterium* suspension on the transformation efficiency of *Agrobacterium* strains. The concentration of the *Agrobacterium* suspension was 10<sup>6</sup> cells/ml (A), 10<sup>7</sup> cells/ml (B), 10<sup>8</sup> cells/ml (C), and 10<sup>9</sup> cells/ml (D). The concentration of the *Agrobacterium* suspension was 10<sup>6</sup> cells/ml (A), 10<sup>7</sup> cells/ml (B), 10<sup>8</sup> cells/ml (C), and 10<sup>9</sup> cells/ml (D). The concentration of the *Agrobacterium* suspension was 10<sup>6</sup> cells/ml (A), 10<sup>7</sup> cells/ml (B), 10<sup>8</sup> cells/ml (C), and 10<sup>9</sup> cells/ml (D). The concentration of the *Agrobacterium* suspension was 10<sup>6</sup> cells/ml (A), 10<sup>7</sup> cells/ml (B), 10<sup>8</sup> cells/ml (C), and 10<sup>9</sup> cells/ml (D).

$\frac{d}{dt} \left( \frac{\partial L}{\partial \dot{x}} \right) = \frac{\partial L}{\partial x}$

1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066, 2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078, 2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210, 2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246, 2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282, 2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318, 2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342, 2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378, 2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414, 2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426, 2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438, 2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450, 2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462, 2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486, 2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510, 2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522, 2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534, 2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546, 2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570, 2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582, 2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594, 2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606, 2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618, 2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630, 2631, 2632, 2633, 2634, 2635, 2636, 2637, 2638, 2639, 2640, 2641, 2642, 2643, 2644, 2645, 2646, 2647, 2648, 2649, 2650, 2651, 2652, 2653, 2654, 2655, 2656, 2657, 2658, 2659, 2660, 2661, 2662, 2663, 2664, 2665, 2666, 2667, 2668, 2669, 2670, 2671, 2672, 2673, 2674, 2675, 2676, 2677, 2678, 26

1. *Journal of the American Medical Association*, 1997; 277: 1033-1036.

[illegible]

and elevated spleen mass, and hypergammaglobulinemia, precede signs of severe lymphocyte acquired immune deficiency syndrome (AIDS). These findings suggest that the role of immunomodulator in AIDS treatment as well as the mechanisms by which retrovirus infection induces cytokine dysregulation, facilitating immunodeficiencies in AIDS.

11 Anti-IL-4 monoclonal antibody and IFN-gamma administration retard development of immune dysfunction and cytokine dysregulation during murine AIDS.

AB This study was designed to determine if anti-interleukin-4 (anti-IL-4) monoclonal antibody (mAb), interferon gamma (IFN-gamma), and their combination after LP-PM retrovirus infection of female B6 mice would prevent retrovirus-induced immune dysregulation and cytokine dysregulation. Spleen natural killer (NK) cell activity, T- and B-cell proliferation, and T-helper type 1 (Th1) and Th2 cytokines (IL-2, IFN-gamma, IL-6 and IL-10) and monokine (IL-6 and tumor necrosis factor-alpha (TNF-alpha)) secretions were monitored, as they are usually altered dramatically after murine retrovirus infection. Administration of IFN-gamma, and anti-IL-4 significantly prevented retrovirus-induced suppression of splenic NK cell activity, and splenic T- and B-cell proliferation. They also significantly slowed retrovirus-induced elevation of Th2 cytokine (IL-6 and IL-10) release and monokine (IL-6 and TNF-alpha) secretion by splenocytes. They prevented the loss of Th1 cytokine (IL-2 and IFN-gamma) release by splenocytes, and elevated spleen mass and hypergammaglobulinemia, precursor signs of development of acquired immune deficiency syndrome (AIDS). These findings could provide insight into the role of immunomodulator in AIDS treatment as well as the mechanisms by which retrovirus infection induces cytokine dysregulation, facilitating immunodeficiencies in AIDS.

12 AIDS associated with anti-IL-4, interferon-4, interferon-4

13 Antineoplastic

PL: BAC (Biological activity or effect or, except adverse ; BCL

Biological study)

anti-interleukin 4 monoclonal antibody and IFN-gamma, retardation of immune dysfunction and cytokine dysregulation during murine AIDS

14 Lymphokines and Cytokines

PL: ALV (Adverse effect, including toxicity ; MFM (Metabolic formation ;

BCL (Biological study ; FORM (Formation, nonpreparative

cytokine dysregulation, including loss of anti-interleukin 4 monoclonal antibody and IFN-gamma, administration in murine AIDS effect on formation of

15 Spleen, mass

hyperplasia, anti-interleukin 4 monoclonal antibody and IFN-gamma, administration in murine AIDS effect on

16 Lymphokines and Cytokines

PL: BAC (Biological activity or effect or, except adverse ; BCL

Biological study)

(interleukin 4, anti-interleukin 4 monoclonal antibody and IFN-gamma, retardation of immune dysfunction and cytokine dysregulation during murine AIDS

17 Lymphokines and Cytokines

PL: ALV (Adverse effect, including toxicity ; MFM (Metabolic formation ;

BCL (Biological study ; FORM (Formation, nonpreparative

interleukin 4, anti-interleukin 4 monoclonal antibody and IFN-gamma, administration in murine AIDS effect on formation of

18 Lymphokines and Cytokines

PL: ALV (Adverse effect, including toxicity ; MFM (Metabolic formation ;

BCL (Biological study ; FORM (Formation, nonpreparative

interleukin 4, anti-interleukin 4 monoclonal antibody and IFN-gamma, administration in murine AIDS effect on formation of

19 Lymphokines and Cytokines

PL: ALV (Adverse effect, including toxicity ; MFM (Metabolic formation ;

BCL (Biological study ; FORM (Formation, nonpreparative

tumor necrosis factor-alpha, anti-interleukin 4 monoclonal antibody and IFN-gamma, administration in murine AIDS

effect on formation of

20 Interferons

PL: BAC (Biological activity or effect or, except adverse ; BCL

Biological study)

(gamma, anti-interleukin 4 monoclonal antibody and IFN-gamma, retardation of immune dysfunction and cytokine dysregulation during murine AIDS

21 Lymphokines and Cytokines

PL: ALV (Adverse effect, including toxicity ; MFM (Metabolic formation ;

BCL (Biological study ; FORM (Formation, nonpreparative

gamma, anti-interleukin 4 monoclonal antibody and IFN-gamma, administration in murine AIDS effect on

22 111 111

FILE 'HOME' ENTERED AT 16:02:48 ON 19 AUG 2001

FILE 'MELINE, CAPLOW, EMBASE, RIOSIS' ENTERED AT 16:03:06 ON 19 AUG 2001

11 1469 S ANTIBOD (IL-4) (INTERFERON GAMMA OR IFN GAMMA OR GAMMA  
12 1437 S ANTIBOD (IL-4) (TNF) OR TNF ALPHA OR TUMOR NECROSIS  
13 947 S ANTIBOD (IL-4) (TNF ALPHA OR TUMOR NECROSIS FACTOR ALPHA  
14 1461 S IL-4 ADMINIST  
15 1437 S IL-4 ADMINIST  
16 1437 S IL-4 ADMINIST  
17 1437 S IL-4  
18 1437 S IL-4  
19 1437 S IL-4  
20 1437 S IL-4  
21 1437 S IL-4  
22 1437 S IL-4  
23 1437 S IL-4  
24 1437 S IL-4  
25 1437 S IL-4  
26 1437 S IL-4  
27 1437 S IL-4  
28 1437 S IL-4  
29 1437 S IL-4  
30 1437 S IL-4  
31 1437 S IL-4  
32 1437 S IL-4  
33 1437 S IL-4  
34 1437 S IL-4  
35 1437 S IL-4  
36 1437 S IL-4  
37 1437 S IL-4  
38 1437 S IL-4  
39 1437 S IL-4  
40 1437 S IL-4  
41 1437 S IL-4  
42 1437 S IL-4  
43 1437 S IL-4  
44 1437 S IL-4  
45 1437 S IL-4  
46 1437 S IL-4  
47 1437 S IL-4  
48 1437 S IL-4  
49 1437 S IL-4  
50 1437 S IL-4  
51 1437 S IL-4  
52 1437 S IL-4  
53 1437 S IL-4  
54 1437 S IL-4  
55 1437 S IL-4  
56 1437 S IL-4  
57 1437 S IL-4  
58 1437 S IL-4  
59 1437 S IL-4  
60 1437 S IL-4  
61 1437 S IL-4  
62 1437 S IL-4  
63 1437 S IL-4  
64 1437 S IL-4  
65 1437 S IL-4  
66 1437 S IL-4  
67 1437 S IL-4  
68 1437 S IL-4  
69 1437 S IL-4  
70 1437 S IL-4  
71 1437 S IL-4  
72 1437 S IL-4  
73 1437 S IL-4  
74 1437 S IL-4  
75 1437 S IL-4  
76 1437 S IL-4  
77 1437 S IL-4  
78 1437 S IL-4  
79 1437 S IL-4  
80 1437 S IL-4  
81 1437 S IL-4  
82 1437 S IL-4  
83 1437 S IL-4  
84 1437 S IL-4  
85 1437 S IL-4  
86 1437 S IL-4  
87 1437 S IL-4  
88 1437 S IL-4  
89 1437 S IL-4  
90 1437 S IL-4  
91 1437 S IL-4  
92 1437 S IL-4  
93 1437 S IL-4  
94 1437 S IL-4  
95 1437 S IL-4  
96 1437 S IL-4  
97 1437 S IL-4  
98 1437 S IL-4  
99 1437 S IL-4  
100 1437 S IL-4

23 111 111 111 111

111 111 111 111 111 111 111 111 111 111

111 111 111 111 111 111 111 111 111 111

111 111 111 111 111 111 111 111 111 111

111 111 111 111 111 111 111 111 111 111

111 111 111 111 111 111 111 111 111 111

111 111 111 111 111 111 111 111 111 111

111 111 111 111 111 111 111 111 111 111

111 111 111 111 111 111 111 111 111 111

111 111 111 111 111 111 111 111 111 111

111 111 111 111 111 111 111 111 111 111

111 111 111 111 111 111 111 111 111 111

111 111 111 111 111 111 111 111 111 111

111 111 111 111 111 111 111 111 111 111

111 111 111 111 111 111 111 111 111 111



1. ANSWER 1: P  
 APPLICATION NUMBER:  
 DOCUMENT NUMBER:  
 TITLE:  
 AIDS  
 Treatment of autoimmune diseases, including  
 Skurkovich, Boris; Skurkovich, Simon  
 V.  
 Advanced Biopharmacy Concepts, Inc., USA  
 2006, 12 pp., Cont.-in-part of U.S. 7,416,443.  
 (EN): USANAM  
 DOCUMENT TYPE:  
 LANGUAGE:  
 FAMILY AT. NUM. COUNT:  
 PATENT IN. EXAMINING

[illegible]

A5 The present disclosure concerns the treatment of a patient with autoimmune disease, including AIDS, by neutralizing, removing or inhibiting different types of interferons, tumor necrosis factor, HLA class II antigens, IgE, and other pathologic factors and/or their receptors, as well as neutralizing, removing or inhibiting autoantibodies, including antibodies to target cells, CD4 cells and DNA. Treatment comprises administration of an autoimmune inhibitor, or extracorporeal exposure of the patient's fluid to an immunosorbent comprising an autoimmune inhibitor, followed by return of the treated fluid to the patient, or it comprises a combined therapy involving extracorporeal immunosorption in combination with the administration of an autoimmune inhibitor. Combination of a plurality of two or more components selected from anti- $\alpha$ -interferon receptor, anti- $\beta$ -interferon receptor or receptor, anti- $\gamma$ -interferon receptor, anti-tumor necrosis factor receptor, and anti-interleukin-6 antibodies are disclosed.

REFERENCE COUNT: 21  
 REFERENCE S.S.: 1. American Arthritis Rheum 1993, 44: 4, 5111;  
 2. MEDLINE  
 3. Armit W. J. Clin 1993, 19: 11;  
 4. Bivard C. Rheum 1993, 44: 4, 5111;  
 5. Bivard Lynn. Rhe and Arthrine Res 1993, 11: 1, 1;  
 6. 1993, 11: 1;  
 7. Temperton J. J. Rheum 1993, 44: 4, 5111;  
 8. ALL INFORMATION AVAILABLE IN THE REF FORMAT

Skurkovich, Boris; Skurkovich, Simon V.  
The present invention describes the treatment of a patient with an immunodeficiency disease, including AIDS, by neutralizing, removing or inhibiting different types of infectious agents, tumor necrosis factor, HLA class II antigens, IgE, and other pathologic factors and/or their receptors, as well as neutralizing, removing or inhibiting autoantibodies, including antibodies to target cells, CD4 cells and TNA. Treatment comprises administration of an autoimmune inhibitor, or extracorporeal exposure of the patient's fluid to an immunosorbent comprising an autoimmune inhibitor, followed by return of the treated fluid to the patient, or it comprises a combined therapy involving extracorporeal immunosorption in conjunction with the administration of an autoimmune inhibitor. Combination of a plurality of two or more components selected from anti-alpha interferon or receptor, anti-beta interferon or receptor, anti-gamma interferon or receptor, anti-tumor necrosis factor or receptor, and anti-interleukin antibodies are disclosed.

```

11:  AIDS disease
12:  Analyzing sponylitis
13:  Autoimmune disease
14:  Bicket's syndrome
15:  Crohn's disease
16:  Cystic fibrosis
17:  Diabetes mellitus
18:  Ectopic pregnancy
19:  Exocrine pancreas
20:  Exocrine pancreas
21:  Exocrine pancreas
22:  Exocrine pancreas
23:  Exocrine pancreas
24:  Exocrine pancreas
25:  Exocrine pancreas
26:  Exocrine pancreas
27:  Exocrine pancreas
28:  Exocrine pancreas
29:  Exocrine pancreas
30:  Exocrine pancreas
31:  Exocrine pancreas
32:  Exocrine pancreas
33:  Exocrine pancreas
34:  Exocrine pancreas
35:  Exocrine pancreas
36:  Exocrine pancreas
37:  Exocrine pancreas
38:  Exocrine pancreas
39:  Exocrine pancreas
40:  Exocrine pancreas
41:  Exocrine pancreas
42:  Exocrine pancreas
43:  Exocrine pancreas
44:  Exocrine pancreas
45:  Exocrine pancreas
46:  Exocrine pancreas
47:  Exocrine pancreas
48:  Exocrine pancreas
49:  Exocrine pancreas
50:  Exocrine pancreas
51:  Exocrine pancreas
52:  Exocrine pancreas
53:  Exocrine pancreas
54:  Exocrine pancreas
55:  Exocrine pancreas
56:  Exocrine pancreas
57:  Exocrine pancreas
58:  Exocrine pancreas
59:  Exocrine pancreas
60:  Exocrine pancreas
61:  Exocrine pancreas
62:  Exocrine pancreas
63:  Exocrine pancreas
64:  Exocrine pancreas
65:  Exocrine pancreas
66:  Exocrine pancreas
67:  Exocrine pancreas
68:  Exocrine pancreas
69:  Exocrine pancreas
70:  Exocrine pancreas
71:  Exocrine pancreas
72:  Exocrine pancreas
73:  Exocrine pancreas
74:  Exocrine pancreas
75:  Exocrine pancreas
76:  Exocrine pancreas
77:  Exocrine pancreas
78:  Exocrine pancreas
79:  Exocrine pancreas
80:  Exocrine pancreas
81:  Exocrine pancreas
82:  Exocrine pancreas
83:  Exocrine pancreas
84:  Exocrine pancreas
85:  Exocrine pancreas
86:  Exocrine pancreas
87:  Exocrine pancreas
88:  Exocrine pancreas
89:  Exocrine pancreas
90:  Exocrine pancreas
91:  Exocrine pancreas
92:  Exocrine pancreas
93:  Exocrine pancreas
94:  Exocrine pancreas
95:  Exocrine pancreas
96:  Exocrine pancreas
97:  Exocrine pancreas
98:  Exocrine pancreas
99:  Exocrine pancreas
100: Exocrine pancreas

```

INVENTOR : AIDIS KURKOVICH, Simon  
ATTORNEY IN MATTER : Skurkovich, Boris; Skurkovich, Simon  
DOCUMENT NUMBER : V.  
TITLE :  
AIDS TREATMENT OF HIV INFECTION AND  
METHODS FOR THE TREATMENT OF AIDS INFECTION  
including AIDS  
INVENTOR : Skurkovich, Boris; Skurkovich, Simon  
PATENT ASSIGNEE :  
ADDRESS : Advanced Biotechnology Concepts, Inc., USA  
P.O. Box 970, Aptos, CA 95021  
COUNTRY : USA  
DOCUMENT TYPE : Patent

[illegible][illegible]

[illegible][illegible]

| PATENT NO.             | HOME | DATE       | APPLICATION NO. | DATE          |
|------------------------|------|------------|-----------------|---------------|
| US 5026743             | A    | 1990/06/06 | US 1993-25436   | 1993/02/22    |
| US 5568811             | A    | 1994/03/20 | US 1996-771831  | 1996/12/23    |
| US 2001/025511         | A1   | 2001/02/09 | US 2001-736765  | 2001/02/09    |
| PROPRIET. APPLN. INFO. |      |            | US 1993-25436   | A2 1993/12/23 |
|                        |      |            | US 1996-771831  | A1 1996/12/23 |
|                        |      |            | US 1997-495770  | A3 1997/12/22 |

AB The present invention concerns a treatment for autoimmune diseases, including AIDS, by removing interferons, TNFs and receptors thereof, from plasma, fluids. An extracorporeal device exposes fluids from a patient, including plasma, cerebrospinal fluid, etc., to an immunosorbent to accomplish removal. Following treatment, the fluid is returned to its source. A diagram showing an extracorporeal device for removing path. 1 substances from joint and spinal fluids is included.

TI Treatment of autoimmune diseases, including AIDS, by removal of interferons, TNFs and their receptors

1. **Skurkovich, Simon V., Skurkovich, Boris**  
The present disclosure concerns a treatment for autoimmune diseases, including AIDS, by removing interferon, TNFs and receptors thereof, therefore, from the fluid. An extra-renal device is exposed fluids from a patient, including blood, plasma, cerebro spinal fluid, etc., and returns the fluids to the patient. Following treatment, the fluid is returned to the patient. A method should an extra-renal device for removing pain substances from blood and spinal fluid is included.

extracorporeal TCM is ascribed for treatment of autoimmune diseases, including AIDS.

- 17. **AIDS** disease
  - Acidic fluid
  - Autoimmune diseases
  - Body fluid
  - Cerebrospinal fluid
  - Extracorporeal circulation
  - Joint (anatomical)
  - Plasma (blood)
  - Synovial fluid
  - Interferon, TNF, and receptor removal with extracorporeal immunoadsorbent for treatment of autoimmune diseases, including

17. Antibodies  
Monoclonal antibodies  
First IV treatment use : 200 mg Intravenous use : 100 mg B.i.d. oral  
every 4 days  
Interferon, GNS, and receipt treatment with extra support  
immunosuppression treatment : antineoplastic diseases, infectious

```

11  ATOS
12  Antigens
13  Interferon receptors
14  Interferon alpha
15  Interferon alpha receptors
16  Interferon beta
17  Interferon gamma
18  Interferon gamma receptors
19  Interferons
20  Interferon gamma receptor
21  Interferon gamma receptor
22  Interferon gamma receptor
23  Interferon gamma receptor
24  Interferon gamma receptor
25  Interferon gamma receptor
26  Interferon gamma receptor
27  Interferon gamma receptor
28  Interferon gamma receptor
29  Interferon gamma receptor
30  Interferon gamma receptor
31  Interferon gamma receptor
32  Interferon gamma receptor
33  Interferon gamma receptor
34  Interferon gamma receptor
35  Interferon gamma receptor
36  Interferon gamma receptor
37  Interferon gamma receptor
38  Interferon gamma receptor
39  Interferon gamma receptor
40  Interferon gamma receptor
41  Interferon gamma receptor
42  Interferon gamma receptor
43  Interferon gamma receptor
44  Interferon gamma receptor
45  Interferon gamma receptor
46  Interferon gamma receptor
47  Interferon gamma receptor
48  Interferon gamma receptor
49  Interferon gamma receptor
50  Interferon gamma receptor
51  Interferon gamma receptor
52  Interferon gamma receptor
53  Interferon gamma receptor
54  Interferon gamma receptor
55  Interferon gamma receptor
56  Interferon gamma receptor
57  Interferon gamma receptor
58  Interferon gamma receptor
59  Interferon gamma receptor
60  Interferon gamma receptor
61  Interferon gamma receptor
62  Interferon gamma receptor
63  Interferon gamma receptor
64  Interferon gamma receptor
65  Interferon gamma receptor
66  Interferon gamma receptor
67  Interferon gamma receptor
68  Interferon gamma receptor
69  Interferon gamma receptor
70  Interferon gamma receptor
71  Interferon gamma receptor
72  Interferon gamma receptor
73  Interferon gamma receptor
74  Interferon gamma receptor
75  Interferon gamma receptor
76  Interferon gamma receptor
77  Interferon gamma receptor
78  Interferon gamma receptor
79  Interferon gamma receptor
80  Interferon gamma receptor
81  Interferon gamma receptor
82  Interferon gamma receptor
83  Interferon gamma receptor
84  Interferon gamma receptor
85  Interferon gamma receptor
86  Interferon gamma receptor
87  Interferon gamma receptor
88  Interferon gamma receptor
89  Interferon gamma receptor
90  Interferon gamma receptor
91  Interferon gamma receptor
92  Interferon gamma receptor
93  Interferon gamma receptor
94  Interferon gamma receptor
95  Interferon gamma receptor
96  Interferon gamma receptor
97  Interferon gamma receptor
98  Interferon gamma receptor
99  Interferon gamma receptor
100  Interferon gamma receptor

```

1. The first step is to identify the problem or question that needs to be answered. This involves understanding the context and the specific requirements of the task.

Plasma and/or antibody to HIV, and receptor removal with extracorporeal immunadsorption for treatment of autoimmune diseases, including AIDS

[illegible]

To examine a possible association between plasma viremia and interferon- $\alpha$ , IFN- $\alpha$  in patients with the acquired immunodeficiency syndrome AIDS, we performed IFN plasma immunoadsorption by apheresis. IFN- $\alpha$  apheresis in four volunteers with AIDS who had sustained levels of endogenous plasma IFN- $\alpha$ . IFN- $\alpha$  apheresis with two plasma volume exchanges was performed daily for 5 days. Clinical signs and symptoms and hematologic, virologic, and immunologic parameters were monitored. Two subjects developed anemia from phlebotomy, and the radiocatheter-associated bacteremia. The IFN- $\alpha$  apheresis was effective in transiently reducing IFN- $\alpha$  levels. In IFN- $\alpha$  low day to the rapid reinitiation of endogenous HIV-1 was unchanged, but there if it did not have a direct relation to reduced plasma virus burden. It with the treatment. The reduction in viral HIV-inactivated IFN- $\alpha$  by apheresis all while still intact plasma virus titration. The HIV-1 IFN- $\alpha$  showed characteristics in ELISA, Western blot, and plaque assay similar to the supernatant of the initial plating. The neutralizing activity, and HIV-inactivated IFN- $\alpha$ s demonstrate nearly identical antiviral activities. The HIV-1 IFN- $\alpha$  elutes from the column was not acid labile. The inability of large amounts of plasma IFN- $\alpha$  found in some patients with AIDS to affect viral burden likely reflects properties of the virus or of host factors independent of IFN- $\alpha$ .

Acknowledgments: Dr Steven A. Moll, Douglas E. Alpert, R. Allen M. Finkelstein, Michael S. Pollard, J. Skurkovich S., Jonathan H. Cohen, and Robert C. Galanter.

This work was supported by National Institutes of Health Grants AI-07689 and AI-07690.

45 instances of interferon synthesis with the hyperproduction of unusual kinds of interferon may be the initial step which triggers an immune disease for which there is a genetic predisposition including the inheritance of several genes, viral and/or other diseases. Restricted synthesis of the interferon may be a protective mechanism of an individual inhibiting the administration of the effects of animals or humans with an immune disease or an underlying or latent autoimmune condition can exacerbate or trigger the disease. Healthy people do not have interferon in their blood. This fundamental disturbance of interferon synthesis can result either from a genetic predisposition or from the influence of certain viruses or viral particles or both factors together.

**AIDS** has many features similar to autoimmune disease, including the hyperproduction of aberrant interferon, a type with restricted anti-HIV activity, protectively induced by HIV to allow its continued replication and survival. This interferon stimulates the production of certain cytokines and anti antibodies which help unleash the potentially self-destructive powers of the immune system, bringing immunological chaos. In other words, while usual viruses induce normal interferon, which protects the cells against viral infection, HIV induces an abnormal, defective kind of interferon which ensures virus survival. Since there is no known effective method of destroying HIV directly, removing lymph in this chain of reactions is an indirectly destroying HIV and possibly help prevent the progression of AIDS. DR. GARY TERNAN AT 11:50 AM

[illegible]



[illegible]

[illegible]

AB . . . associated primarily with the production of the family of IFN- $\alpha$ . In certain immunologically mediated diseases, including the autoimmune diseases and AIDS, disturbances in the synthesis of IFN- $\alpha$  occur with a switch to the production of predominantly acid-labile types, which have a . . .

CONSTITUTIONAL LAW: THE RIGHT OF A PERSON TO REMAIN SILENT